SCHEMBL348309

SCHEMBL348309

O=C(Nc1ccc(C(=O)N2CCN(Cc3cc(C(=O)O)ccn3)CC2)cc1F)NC1CCC1.[NaH]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5C P41229 1/20 0.45
KDM4C Q9H3R0 1/20 0.45
ACKR3 P25106 2/20 0.44
NPC1 O15118 1/20 0.43
POLB P06746 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
FASN P49327 2/20 0.42
ALDH1A1 P00352 3/20 0.42
PRKAA2 P54646 5/20 0.41
PRKAB2 O43741 4/20 0.41
PRKAG1 P54619 4/20 0.41
PRKAA1 Q13131 4/20 0.41
PRKAG3 Q9UGI9 4/20 0.41
PRKAG2 Q9UGJ0 4/20 0.41
PRKAB1 Q9Y478 4/20 0.41
EPHX2 P34913 4/20 0.41
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL348308 0.91 ACKR3 (0.44) ACKR3NPC1POLBRAB9AL3MBTL1
SCHEMBL348806 0.90 L3MBTL1 (0.44) ACKR3NPC1POLBRAB9AL3MBTL1
SCHEMBL13458595 0.88 L3MBTL1 (0.42) ACKR3NPC1POLBRAB9AL3MBTL1
SCHEMBL347706 0.88 ACKR3 (0.43) ACKR3NPC1POLBRAB9AL3MBTL1
SCHEMBL347189 0.85 ALDH1A1 (0.46) ACKR3NPC1POLBRAB9AL3MBTL1
SCHEMBL346659 0.81 NPC1 (0.56) NPC1POLBRAB9AL3MBTL1FASN
SCHEMBL347188 0.80 ALDH1A1 (0.44) ACKR3NPC1POLBRAB9AL3MBTL1
SCHEMBL347273 0.79 ALDH1A1 (0.43) ACKR3NPC1POLBRAB9AL3MBTL1
SCHEMBL347099 0.79 PRKAA2 (0.44) ACKR3L3MBTL1PRKAA2PRKAB2PRKAG1
SCHEMBL348551 0.78 L3MBTL1 (0.41) NPC1POLBRAB9AL3MBTL1FASN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 US disclosed
EP-2318368-B1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES MERCK SHARP & DOHME (NL) 2013-10-16 EP disclosed
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES NPC1, ABCB11, NPC1L1 KDM5C 2635/4885KDM4C 3551/4885ACKR3 1675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.